[Federal Register: June 12, 2002 (Volume 67, Number 113)]
[Page 40316-40317]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Arthritis Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Arthritis Advisory Committee.

[[Page 40317]]

    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA’s regulatory issues.
    Date and Time: The meeting will be held on July 29 and 30, 2002, 
from 8 a.m. to 5 p.m.
    Location: Holiday Inn, Versailles Ballroom, 8120 Wisconsin Ave., 
Bethesda, MD.
    Contact Person: Kathleen Reedy or LaNise Giles, Center for Drug 
Evaluation and Research (HFD–21), Food and Drug Administration, 
5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), 
Rockville, MD 20857, 301–827–7001, FAX 
301–827–6776, or e-mail: reedyk@cder.fda.gov, or FDA 
Advisory Committee Information Line, 1–800–741–8138 
(301–443–0572 in the Washington, DC area), code 12532. 
Please call the Information Line for up-to-date information on this 
    Agenda: On both days, the committee will discuss the clinical 
relevance of different classifications of pain as well as discussion of 
appropriate clinical trial models and designs for medications which 
would be indicated for each classification of pain.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by July 17, 2002. 
Oral presentations from the public will be scheduled on July 29, 2002, 
between approximately 1 p.m. and 3 p.m., and on July 30, 2002, between 
approximately 11 a.m. and 12 noon. Time allotted for each presentation 
may be limited. Those desiring to make formal oral presentations should 
notify the contact person before July 17, 2002, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
    Persons attending FDA’s advisory committee meetings are 
advised that the agency is not responsible for providing access to 
electrical outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact LaNise Giles at 
301–827–7001, at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: June 3, 2002.
William K. Hubbard,
Senior Associate Commissioner for Policy, Planning, and Legislation.
[FR Doc. 0214680 Filed 6–11–02; 8:45 am]